source
- Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopeniaPfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood d…
- FDA Grants Accelerated Approval for Jemperli Immunotherapy in Locally Advanced Rectal CancerThe U.S. Food and Drug Administration has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab‑gxly). The approval applies to adults with previously untreated stage…